RT Journal Article
SR Electronic
T1 Safety and immunogenicity of SW-BIC-213, a modified COVID-19 Lipo-Polyplex mRNA vaccine, in Laotian healthy adults aged 18 years and above: a Phase 1/2 trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.11.23295344
DO 10.1101/2023.09.11.23295344
A1 Chen, Yujie
A1 Li, Jingxin
A1 Duangdany, Davone
A1 Phamisith, Chanthala
A1 Yu, Bo
A1 Lan, Shengke
A1 Jin, Lairun
A1 Lv, Dawei
A1 Li, Yang
A1 Luo, Bin
A1 Han, Peng
A1 Wu, Jinyan
A1 Wang, Yuzhu
A1 Xu, Congcong
A1 Shen, Mingyun
A1 Zhao, Fanfan
A1 Liu, Peipei
A1 Pei, Rongjuan
A1 Shen, Haifa
A1 Guan, Wuxiang
A1 Li, Hangwen
A1 Mayxay, Mayfong
YR 2023
UL http://medrxiv.org/content/early/2023/09/12/2023.09.11.23295344.abstract
AB Background The mRNA vaccine against SARS-CoV-2 has demonstrated remarkable efficacy in protecting against coronavirus disease 2019 (COVID-19), including providing high protection against severe disease during the emergence of variant waves. In this study, we aimed to investigate the safety and immunogenicity of a 2-dose regimen of the LPP-based mRNA vaccine, SW-BIC-213, in Laos.Methods For this phase 1/2 clinical trial, we recruited healthy adults aged 18-60 years (phase 1) or ≥18 years (phase 2) from Mahosot Hospital (Vientiane) and Champhone District Hospital (Savannakhet). Participants with SARS-CoV-2 infection, previous COVID-19 vaccination, known allergies to any vaccine component, or pregnancy were excluded. In the phase 1 trial, 41 eligible participants were sequentially assigned to either the 25 μg dose group (25 μg) or the 45 μg dose group (45 μg) in accordance with their enrollment order, with 21 participants in 45 μg dose group and 20 participants in 25 μg dose group. In the phase 2 trial, 480 participants were randomly allocated (2:2:1 ratio) to either the 25 μg dose group, 45 μg dose group, or placebo group.The primary endpoints for the phase 1 trial were the incidence of local/systemic solicited adverse reactions/events (0-6 days after each vaccination dose), unsolicited adverse events (0-21 days and 0-28 days after the first and second dose of immunization, respectively), and serious adverse events from the first dose of vaccination to 28 days after completing the full course of immunization. In the phase 2 trial, the primary endpoints were the seroconversion rate and geometric mean titer (GMT) of SARS-CoV-2 S-protein specific IgG antibodies and neutralizing antibodies 14 days after the second dose in participants. As for neutralizing antibodies, we detected pseudo-virus neutralizing antibody against wild type (WT), Delta, BA.1 and BA.2. We also detected live viral neutralizing antibody against WT strain 14 days after the second dose. Furthermore, the safety endpoints were also measured during the trial.This seamless phase 1/2 trial was registered with ClinicalTrials.gov under the identifier NCT05144139.Results Between December 3, 2021, and March 31, 2022, a total of 41 participants were recruited in the phase 1 trial, while the phase 2 trial enrolled 480 participants from January 20 to July 6, 2022. In the phase 1 trial, a total of 32 subjects (80.0%) reported 103 cases of adverse reactions. All adverse reactions were limited to Grade 1-2. In the phase 2 trial, a total of 479 subjects, 372 subjects (77.7%) reported 929 cases of adverse reactions. All adverse reactions in severity of Grade 3 were manifested as fever (3.4%, 2.1% and 2.9% in 45 μg dose, 25 μg dose and placebo group respectively, only observed in adults), except which all other reactions were limited to Grade 1-2. All adverse reactions noted during the study were tolerable, predominantly transient, and resolved spontaneously. No serious adverse events (SAEs) related to vaccination were observed.In Phase 2 study, SW-BIC-213 could elicit a high level of seroconversion rate of pseudo-virus neutralizing antibody against WT (100.0% in 25 μg dose group, 99.3% in 45 μg dose group), Delta (99.2% in 25 μg dose group, 98.0% in 45 μg dose group), Omicron BA.1 (84.1% in 25 μg dose group, 84.7% in 45 μg dose group) and Omicron BA.2 (96.0% in 25 μg dose group, 88.8% in 45 μg dose group) at 14 days after the second dose. The pseudo-virus neutralizing antibody titer against WT, Delta, BA.1 and BA.2 was all significant higher (P<0.0001) in both 45 μg dose group (1175.02, 620.62, 72.39 and 172.80) and 25 μg dose group (885.80, 579.40, 47.24 and 101.96) compared with the placebo group (9.67, 10.66, 13.99 and 29.53) at 14 days after the second dose. As for live viral neutralizing antibodies against WT strain, the seroconversion rate could reach more than 94% at 14 days after second dose. The neutralizing antibody titer against WT strain was significantly higher (P<0.0001) in both 45 μg dose group (315.00) and 25 μg dose group (323.18) compared with the placebo group (8.51) at 14 days after second dose.Conclusion COVID-19 mRNA vaccine SW-BIC-213 manifests a favorable safety profile and is highly immunogenic in eligible subjects aged ≥18 years.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05144139Funding StatementThis study was funded by StemiRNA TherapeuticsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial received approval from the Ethics Committee and Food & Drug Department of the Ministry of Health, Lao PDR (7745).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript All data produced are available online at